← Human Trials & Peer-Reviewed Studies
Losartan and end-organ protection--lessons from the RENAAL study.
Plain-language guide to PMID 15813620 (2005): placebo-controlled clinical trial of Losartan in 2 patients.
Key Facts
- PMID
- 15813620
- Journal
- Clinical cardiology
- Year
- 2005
- Study type
- Clinical Trial
- Authors
- Kowey PR et al. (5 authors)
- DOI
- 10.1002/clc.4960280307
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Losartan, published as a clinical trial.
This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects.
Who Took Part
The abstract describes 2 patients taking part.
PubMed indexes the participants as adults, middle-aged adults and older adults, women only.
The RENAAL study compared losartan with placebo (in addition to conventional antihypertensive medications) in type 2 diabetic patients with proteinuria.
The effect of treatment with losartan was examined using three time-to-event analyses of composite cardiorenal outcomes as described below.
How the Study Was Run
The researchers set it up as a placebo-controlled study.
A placebo (an inactive look-alike) gave the Losartan group a baseline to be compared against.
Morbidity and mortality due to cardiovascular causes were ascertained, and the relationship between baseline proteinuria and cardiovascular outcome was determined.
What Was Measured
This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects.
The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Progression, Kidney Failure, Chronic and Losartan.
What This Means in Plain Language
The paper is a placebo-controlled study of Losartan in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Clinical cardiology), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.